Cardiac T2* MRI assessment in patients with thalassaemia major and its effect on the preference of chelation therapy
- PMID: 24719246
- DOI: 10.1007/s12185-014-1575-1
Cardiac T2* MRI assessment in patients with thalassaemia major and its effect on the preference of chelation therapy
Abstract
The aim of the study is to assess the relationship between T2* magnetic resonance imaging (MRI) values and age, serum ferritin level, left ventricular ejection fraction (LVEF), splenectomy status, and to identify appropriate modifications to chelation therapy based on T2* MRI results of children with thalassaemia major. Sixty-four patients with thalassaemia major (37 girls/27 boys) older than 8 years of age were enrolled in the study. Based on the first T2* MRI, the patients' myocardial iron depositions were classified into three groups: T2* MRI <10 ms (high risk group), T2* MRI 10-20 ms (medium-risk group) and T2* MRI >20 ms (low-risk group). There was no significant relationship between T2* MRI value and ages, serum ferritin levels and splenectomy status of thalassaemia major patients. The mean LVEFs were 60, 75, and 72.5 % in the high-, medium-, and low-risk groups, respectively (P = 0.006). The mean cardiac iron concentrations calculated from the T2* MRI values were 4.96 ± 1.93, 1.65 ± 0.37, and 0.81 ± 0.27 mg/g in the high-, medium-, and low-risk groups, respectively. Chelation therapies were re-designed in 24 (37.5 %) patients according to cardiac risk as assessed by cardiac T2* MRI. In conclusion, until recently, T2* MRI has been employed to demonstrate cardiac siderosis without a direct relationship with the markers used in follow-up of patients with thalassaemia. However, modifications of chelation therapies could reliably be planned according to severity of iron load displayed by T2* MRI.
Similar articles
-
The Importance of Cardiac T2* Magnetic Resonance Imaging for Monitoring Cardiac Siderosis in Thalassemia Major Patients.Tomography. 2021 Apr 18;7(2):130-138. doi: 10.3390/tomography7020012. Tomography. 2021. PMID: 33919601 Free PMC article.
-
Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2* magnetic resonance imaging.Hematology. 2017 Sep;22(8):501-507. doi: 10.1080/10245332.2017.1292614. Epub 2017 Feb 20. Hematology. 2017. PMID: 28218005
-
Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by T2* MRI.Clin Drug Investig. 2010;30(4):267-73. doi: 10.2165/11534480-000000000-00000. Clin Drug Investig. 2010. PMID: 20225910
-
Cardiac iron across different transfusion-dependent diseases.Blood Rev. 2008 Dec;22 Suppl 2(Suppl 2):S14-21. doi: 10.1016/S0268-960X(08)70004-3. Blood Rev. 2008. PMID: 19059052 Free PMC article. Review.
-
Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.Expert Rev Hematol. 2016;9(2):151-68. doi: 10.1586/17474086.2016.1126176. Epub 2015 Dec 19. Expert Rev Hematol. 2016. PMID: 26613264 Review.
Cited by
-
Quantification of Liver Iron Overload: Correlation of MRI and Liver Tissue Biopsy in Pediatric Thalassemia Major Patients Undergoing Bone Marrow Transplant.Indian J Hematol Blood Transfus. 2020 Oct;36(4):667-673. doi: 10.1007/s12288-020-01256-1. Epub 2020 Feb 22. Indian J Hematol Blood Transfus. 2020. PMID: 33100708 Free PMC article.
-
Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience.Radiol Med. 2018 Aug;123(8):572-576. doi: 10.1007/s11547-018-0889-0. Epub 2018 Apr 16. Radiol Med. 2018. PMID: 29663188
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical